Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Cabozantinib in RM SCCHN
NCT03468218Phase 2Active, not recruiting
- Sponsor
- Emory University
- Start
- Sep 2018
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib, pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Emory University. Started Sep 2018; status: active, not recruiting.
02
Drugs
cabozantinibpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03468218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468218.